Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Nutriband Inc NTRB

Healthcare
Nutriband Inc. is engaged in the development of a portfolio of transdermal pharmaceutical products. Its development pipeline consists of transdermal products that are based on proprietary AVERSA abuse-deterrent transdermal technology. The Company's development pipeline includes AVERSA Buprenorphine and AVERSA Methylphenidate. The Company is also developing a portfolio of transdermal... see more

Recent & Breaking News (NDAQ:NTRB)

Nutriband Inc. Issued Full Patent from the Chinese National Intellectual Property Administrant for Its "Abuse and Misuse Deterrent Transdermal System" Application

Accesswire 18 hours ago

Nutriband Inc Mosquito Repellent Patch Approved by Ministry of Health of Costa Rica

Accesswire October 17, 2024

Join Nutriband's Exclusive Live Investor Webinar and Q&A Session on October 17

Accesswire October 2, 2024

Nutriband Receives China Patent Notice of Allowance for Its Aversa(TM) Abuse Deterrent Transdermal Technology

Accesswire September 24, 2024

Nutriband Licenses Bitrex(R) Brand Aversive Agent for Its Lead Product - Aversa(TM) Fentanyl Transdermal Patch

Accesswire September 20, 2024

Nutriband Inc. Authorizes $1M Share Buyback Program

Accesswire September 16, 2024

Nutriband Inc. Quarterly Report Highlights Strong Cash Position, and Strategic Progress Toward NDA Filing for AVERSA Fentanyl in 2025

Accesswire September 4, 2024

Join Nutriband's Exclusive Live Investor Webinar and Q&A Session on July 25

Accesswire July 19, 2024

Nutriband Receives Notice of Allowance for U.S. Trademark Covering AVERSA(TM) Abuse Deterrent Technology

Accesswire July 15, 2024

Nutriband Provides Product Development Update for Its Lead Product Aversa Fentanyl

Accesswire June 20, 2024

Nutriband Inc. Quarterly Report Emphasizes Focus on Kinesiology Tape Output as Q1 Sports Tape Revenues Increase 219% Year Over Year

Accesswire June 3, 2024

Nutriband Appoints Accomplished Business Leader Sergei Glinka to its Board of Directors

Accesswire May 16, 2024

Can-Fite BioPharma and Nutriband Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV

Accesswire May 10, 2024

Nutriband Closes $8.4M Private Placement for Commercial Development of Aversa(R) Fentanyl Transdermal Patch Through FDA Submission

Accesswire April 24, 2024

Nutriband Inc. Signs Exclusive Supplier Agreement with Major Sports Brand Licensee Fit for Life Group

Accesswire April 23, 2024

Nutriband Inc. Announces $8.4M Private Placement

Accesswire April 19, 2024

Nutriband Inc. Begins Manufacturing for Major Sports Brand Licensee Fit for Life Group, Whose Collection of Partnered Brands Include Reebok, Adidas and New Balance

Accesswire April 1, 2024

Nutriband Provides Clinical and Regulatory Path Overview for Lead Product - AVERSA(R) Fentanyl Transdermal Patch

Accesswire March 27, 2024

Nutriband Announces Data Supporting Need for Safer Abuse-Deterrent Transdermal Patches Presented at 2024 American Academy of Pain Medicine Annual Meeting

Accesswire March 25, 2024

Prescription Transdermal Patch Abuse and Accidental Pediatric Exposure Remains a Serious Problem in the United States - Surveillance Data to Be Presented at 2024 American Academy of Pain Medicine Annual Meeting

Accesswire March 4, 2024